Actualités de la communauté

18.10.2016 ADC Therapeutics Announces Closing of $105 Million Private Financing

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has raised $105 million through a private placement. The financing was oversubscribed and supported by both new and existing investors, including Auven Therapeutics, the Wild Family Office and AstraZeneca.

Refer to the PDF for the full press release.

Media contact: Dr. Chris Martin